Nichole Doyle
This randomized controlled trial examines whether the addition of a low-dose dexmedetomidine infusion to our current multimodal pain management plan decreases narcotic consumption and reduces side effects in adolescent patients undergoing posterior spinal fusion for idiopathic scoliosis.
Patients will assigned to one of two groups. Either the intervention group where they will receive a dexmedetomidine infusion at 0.2mcg/kg/hr for 24 hours post-operatively or the control group where they will receive a normal saline infusion for 24 hours post-operatively in addition to our hospitals standard pain management protocol. Pain scores will be recorded and patients will fill out a brief questionnaire on POD 1 about their pain control and side effects (pruritus, nausea, vomiting, drowsiness).
Inclusion Criteria: * Diagnosis of idiopathic scoliosis * Undergoing a posterior spinal fusion of at least 5 levels with both thoracic and lumbar involvement Exclusion Criteria: * Known allergy to dexmedetomidine or any of the standard medications used intra or post operatively * Patients with a history of chronic pain currently taking opioids, TCA's, Gabapentinoids * Medical contraindications to administration of dexmedetomidine, unstable cardiac status, (prolonged Qtc, life threatening arrhythmias, use of digoxin) * Moya Moya disease
Patient receives dexmedetomidine for 48 hours post-operatively
Patient receives normal saline for 48 hours post-operatively
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.